PTEN downregulation induces apoptosis and cell cycle arrest in uterine cervical cancer cells

Shin,Jin Woo; Kim,Se-Hee; Yoon,Jin Young

doi:10.3892/etm.2021.10534

PTEN downregulation induces apoptosis and cell cycle arrest in uterine cervical cancer cells

Authors:
- Jin Woo Shin
- Se-Hee Kim
- Jin Young Yoon
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Gil Medical Center, College of Medicine, Gachon University, Incheon 21565, Republic of Korea, Gachon Medical Research Institute, Gil Medical Center, Gachon University, Incheon 21565, Republic of Korea
Published online on: August 2, 2021 https://doi.org/10.3892/etm.2021.10534
Article Number: 1100
Copyright: © Shin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor suppressors PTEN and p53 are often downregulated in various human cancer types, which has been associated with a poor prognosis. Recent evidence implies that PTEN downregulation may induce growth arrest of kidney cells and cancer cells. In the present study, the role of PTEN in the proliferation and survival of cervical cancer cells was investigated. It was found that PTEN silencing promoted apoptosis and cell‑cycle arrest, accompanied by a significant decrease in the proportion of cells in the S1 phase of the cell cycle. Moreover, PTEN silencing in cervical cancer cells increased levels of p53, p27, p21, phospho‑ERK and cleaved caspase‑3, and decreased levels of cyclin A2 and cyclin D1. Furthermore, PTEN knockdown significantly impacted the viability of cervical cancer cells. P53 silencing did not affect the ability of PTEN knockdown to induce apoptosis in cervical cancer cells. Taken together, the present study results imply that PTEN silencing induces apoptosis and decreases proliferation in cervical cancer cells; hence, PTEN inhibition may represent a promising strategy for the treatment of cervical cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
2	Boussios S, Seraj E, Zarkavelis G, Petrakis D, Kollas A, Kafantari A, Assi A, Tatsi K, Pavlidis N and Pentheroudakis G: Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit Rev Oncol Hematol. 108:164–174. 2016.PubMed/NCBI View Article : Google Scholar
3	Liu YZ, Wu K, Huang J, Liu Y, Wang X, Meng ZJ, Yuan SX, Wang DX, Luo JY, Zuo GW, et al: The PTEN/PI3K/Akt and Wnt/β-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation. Int J Oncol. 45:104–112. 2014.PubMed/NCBI View Article : Google Scholar
4	Kim J, Eltoum IE, Roh M, Wang J and Abdulkadir SA: Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 5(e1000542)2009.PubMed/NCBI View Article : Google Scholar
5	Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA and Tsao MS: Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 7:1513–1521. 2012.PubMed/NCBI View Article : Google Scholar
6	Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013.PubMed/NCBI View Article : Google Scholar
7	Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57:3935–3940. 1997.PubMed/NCBI
8	Lu D, Qian J, Yin X, Xiao Q, Wang C and Zeng Y: Expression of PTEN and survivin in cervical cancer: Promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI
9	Lee JS, Choi YD, Lee JH, Nam JH, Choi C, Lee MC, Park CS, Kim HS and Min KW: Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J Surg Oncol. 93:233–240. 2006.PubMed/NCBI View Article : Google Scholar
10	Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lønning PE and Eikesdal HP: High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Res Treat. 163:177–190. 2017.PubMed/NCBI View Article : Google Scholar
11	Nakanishi A, Kitagishi Y, Ogura Y and Matsuda S: The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review). Int J Oncol. 44:1813–1819. 2014.PubMed/NCBI View Article : Google Scholar
12	Blanco-Aparicio C, Renner O, Leal JF and Carnero A: PTEN, more than the AKT pathway. Carcinogenesis. 28:1379–1386. 2007.PubMed/NCBI View Article : Google Scholar
13	Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725–730. 2005.PubMed/NCBI View Article : Google Scholar
14	Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al: A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 120:681–693. 2010.PubMed/NCBI View Article : Google Scholar
15	Samarakoon R, Helo S, Dobberfuhl AD, Khakoo NS, Falke L, Overstreet JM, Goldschmeding R and Higgins PJ: Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses. J Pathol. 236:421–432. 2015.PubMed/NCBI View Article : Google Scholar
16	Gupta A and Dey CS: PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell Endocrinol. 309:55–62. 2009.PubMed/NCBI View Article : Google Scholar
17	Mise-Omata S, Obata Y, Iwase S, Mise N and Doi TS: Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res Commun. 328:1034–1042. 2005.PubMed/NCBI View Article : Google Scholar
18	Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M and Collins FS: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA. 101:1892–1897. 2004.PubMed/NCBI View Article : Google Scholar
19	Li DW, Liu JP, Mao YW, Xiang H, Wang J, Ma WY, Dong Z, Pike HM, Brown RE and Reed JC: Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell. 16:4437–4453. 2005.PubMed/NCBI View Article : Google Scholar
20	Tan BJ and Chiu GN: Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolide-induced apoptosis. Int J Oncol. 42:1605–1612. 2013.PubMed/NCBI View Article : Google Scholar
21	D'Amours D, Sallmann FR, Dixit VM and Poirier GG: Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: Implications for apoptosis. J Cell Sci. 114:3771–3778. 2001.PubMed/NCBI
22	Stein GH, Drullinger LF, Soulard A and Dulić V: Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol. 19:2109–2117. 1999.PubMed/NCBI View Article : Google Scholar
23	Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K and Macip S: Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis. 5(e1528)2014.PubMed/NCBI View Article : Google Scholar
24	Kim JS, Lee C, Bonifant CL, Ressom H and Waldman T: Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 27:662–677. 2007.PubMed/NCBI View Article : Google Scholar
25	Zhou BB and Elledge SJ: The DNA damage response: Putting checkpoints in perspective. Nature. 408:433–439. 2000.PubMed/NCBI View Article : Google Scholar
26	Ming M and He YY: PTEN in DNA damage repair. Cancer Lett. 319:125–129. 2012.PubMed/NCBI View Article : Google Scholar
27	Su TH, Chang JG, Perng LI, Chang CP, Wei HJ, Wang NM and Tsai CH: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol. 76:193–199. 2000.PubMed/NCBI View Article : Google Scholar
28	Tornesello ML, Buonaguro L and Buonaguro FM: Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review. Gynecol Oncol. 128:442–448. 2013.PubMed/NCBI View Article : Google Scholar
29	Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y and Liu Y: Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer. Biomed Rep. 2:653–658. 2014.PubMed/NCBI View Article : Google Scholar
30	Yaginuma Y and Westphal H: Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 51:6506–6509. 1991.PubMed/NCBI
31	Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, et al: PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 18:1777–1789. 2012.PubMed/NCBI View Article : Google Scholar
32	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.PubMed/NCBI View Article : Google Scholar
33	Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A and Deng CX: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 22:37–43. 1999.PubMed/NCBI View Article : Google Scholar
34	Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M and Berns A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 29:418–425. 2001.PubMed/NCBI View Article : Google Scholar
35	Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G and Cervello M: A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 15:573–583. 2016.PubMed/NCBI View Article : Google Scholar